epristeride has been researched along with finasteride in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (55.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batchelor, KW; Bramson, HN; Dorsey, GF; Frye, SV; Haffner, CD; Hiner, RN; Maloney, PR; Noe, RA; Stuart, JD; Unwalla, RJ | 1 |
| Bakshi, RK; Chang, B; Ellsworth, K; Harris, GS; Mosley, RT; Patel, GF; Rasmusson, GH; Tolman, RL | 1 |
| Baginsky, WF; Bakshi, RK; Bull, H; Chang, B; Cimis, G; Ellsworth, K; Harris, GS; Patel, GF; Rasmusson, GH; Tolman, RL | 1 |
| Andrews, RC; Cribbs, CM; Dorsey, GF; Frye, SV; Haffner, CD; Hiner, RN; Maloney, PR; Mook, RA; Ray, JA; Wheeler, TN | 1 |
| Batchelor, KW; Bramson, HN; Dorsey, GF; Frye, SV; Haffner, CD; Hiner, RN; Maloney, PR; Mook, RA; Schweiker, SL; Stuart, JD | 1 |
| Audia, JE; Hirsch, KS; Jones, CD; Lawhorn, DE; McQuaid, LA; Neubauer, BL; Pennington, PA; Pike, AJ; Stamm, NB; Toomey, RE | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Biagini, L; Briatico, G; Cominato, C; di Salle, E; Giudici, D; Panzeri, A | 1 |
| Audia, JE; Bruchovsky, N; Goode, RL; Hsiao, KC; Kaefer, M; Krushinski, JH; Lee, C; Leibovitch, IY; Neubauer, BL; Steidle, CP; Sutkowski, DM | 1 |
| Berthaut, I; Cussenot, O; Mestayer, C; Mowszowicz, I; Portois, MC | 1 |
| Diffley, P; Newton, RP; Price, D; Ranjan, M; Stephen, G; Walton, TJ | 1 |
| Cai, RF; Cui, YG; Di, FS; Jia, Y; Ma, DZ; Tong, JS; Wang, XD; Wang, XH | 1 |
| Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ | 1 |
| Jiang, S; Liao, C; Nicklaus, MC; Xu, Y; Yao, Z; Zhang, M | 1 |
| Qiu, Z; Wang, B; Wang, W; Yang, Y; Zhang, P; Zhao, XF | 1 |
1 review(s) available for epristeride and finasteride
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
1 trial(s) available for epristeride and finasteride
| Article | Year |
|---|---|
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome | 2007 |
16 other study(ies) available for epristeride and finasteride
| Article | Year |
|---|---|
Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
Topics: 3-Hydroxysteroid Dehydrogenases; 5-alpha Reductase Inhibitors; Adrenal Glands; Animals; Azasteroids; Dogs; Humans; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Steroid Isomerases; Structure-Activity Relationship | 1995 |
4-Aza-3-oxo-5 alpha-androst-1-ene-17 beta-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5 alpha-reductases. Dramatic effect of N-aryl substituents on type 1 and type 2 5 alpha-reductase inhibitory potency.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Humans; Molecular Conformation; Thermodynamics | 1995 |
4,7 beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5 alpha-reductase.
Topics: 5-alpha Reductase Inhibitors; Azasteroids; Humans | 1994 |
6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
Topics: 3-Hydroxysteroid Dehydrogenases; 5-alpha Reductase Inhibitors; Adrenal Glands; Animals; Azasteroids; Dogs; Humans; Isoenzymes; Rats; Rats, Sprague-Dawley; Steroid Isomerases; Structure-Activity Relationship | 1994 |
6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.
Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Baculoviridae; Cell Line; Dihydrotestosterone; Humans; Isoenzymes; Male; Moths; Orchiectomy; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Testosterone; Transfection | 1993 |
Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Cell Line; Humans; Male; Quinolones; Structure-Activity Relationship | 1993 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
Topics: Androstadienes; Androstenes; Animals; Azasteroids; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Finasteride; Humans; In Vitro Techniques; Male; Oxidoreductases; Prostate; Rats; Testosterone | 1995 |
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstadienes; Benzoquinones; Cell Division; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; Prostatic Neoplasms; RNA, Messenger; Selection, Genetic; Skin; Testosterone; Tumor Cells, Cultured | 1996 |
Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstadienes; Base Sequence; Benzoquinones; Blotting, Northern; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Epithelium; Fibroblasts; Finasteride; Gene Expression Regulation, Enzymologic; Humans; Isoenzymes; Male; Oligonucleotides; Polymerase Chain Reaction; Prostate; Prostatic Hyperplasia; RNA, Messenger | 1997 |
Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstadienes; Breast; Enzyme Inhibitors; Female; Finasteride; Humans; In Vitro Techniques; Isoenzymes; Male; Middle Aged; Prostate | 2002 |
[Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats].
Topics: 5-alpha Reductase Inhibitors; Androstadienes; Animals; Dose-Response Relationship, Drug; Finasteride; Male; Rats; Rats, Sprague-Dawley; Spermatogenesis | 2005 |
Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstadienes; Binding Sites; Catalytic Domain; Computer Simulation; Drug Evaluation, Preclinical; Finasteride; Humans | 2011 |
Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Topics: 5-alpha Reductase Inhibitors; Androgens; Androstadienes; Animals; Dihydrotestosterone; Dogs; Finasteride; Male; Prostate | 2013 |